Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Discovery of a series of small molecules as potent histone deacetylase inhibitors.

Zhang L, Wang X, Li X, Xu W.

J Enzyme Inhib Med Chem. 2014 Jun;29(3):333-7. doi: 10.3109/14756366.2013.780237.

PMID:
23534931
2.

Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.

Zhang L, Zhang Y, Chou CJ, Inks ES, Wang X, Li X, Hou J, Xu W.

ChemMedChem. 2014 Mar;9(3):638-48. doi: 10.1002/cmdc.201300297.

3.

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Guan P, Sun F, Hou X, Wang F, Yi F, Xu W, Fang H.

Bioorg Med Chem. 2012 Jun 15;20(12):3865-72. doi: 10.1016/j.bmc.2012.04.032.

PMID:
22579621
4.

Identification and characterization of novel indole based small molecules as anticancer agents through SIRT1 inhibition.

Panathur N, Dalimba U, Koushik PV, Alvala M, Yogeeswari P, Sriram D, Kumar V.

Eur J Med Chem. 2013 Nov;69:125-38. doi: 10.1016/j.ejmech.2013.08.018.

PMID:
24013412
5.

Search for novel histone deacetylase inhibitors. Part II: design and synthesis of novel isoferulic acid derivatives.

Lu W, Wang F, Zhang T, Dong J, Gao H, Su P, Shi Y, Zhang J.

Bioorg Med Chem. 2014 May 1;22(9):2707-13. doi: 10.1016/j.bmc.2014.03.019.

PMID:
24702857
6.

Discovery of the first histone deacetylase 6/8 dual inhibitors.

Olson DE, Wagner FF, Kaya T, Gale JP, Aidoud N, Davoine EL, Lazzaro F, Weïwer M, Zhang YL, Holson EB.

J Med Chem. 2013 Jun 13;56(11):4816-20. doi: 10.1021/jm400390r.

PMID:
23672185
7.

Discovery of a series of hydroximic acid derivatives as potent histone deacetylase inhibitors.

Zhang L, Wang X, Li X, Zhang L, Xu W.

J Enzyme Inhib Med Chem. 2014 Aug;29(4):582-9. doi: 10.3109/14756366.2013.827678.

PMID:
24059701
8.

Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.

Guan P, Wang L, Hou X, Wan Y, Xu W, Tang W, Fang H.

Bioorg Med Chem. 2014 Nov 1;22(21):5766-75. doi: 10.1016/j.bmc.2014.09.039.

PMID:
25311567
9.

Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration.

Wang S, Li X, Wei Y, Xiu Z, Nishino N.

ChemMedChem. 2014 Mar;9(3):627-37. doi: 10.1002/cmdc.201300372.

PMID:
24285590
10.

New aryldithiolethione derivatives as potent histone deacetylase inhibitors.

Tazzari V, Cappelletti G, Casagrande M, Perrino E, Renzi L, Del Soldato P, Sparatore A.

Bioorg Med Chem. 2010 Jun 15;18(12):4187-94. doi: 10.1016/j.bmc.2010.05.011.

PMID:
20576572
11.

Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.

Wang F, Lu W, Zhang T, Dong J, Gao H, Li P, Wang S, Zhang J.

Bioorg Med Chem. 2013 Nov 15;21(22):6973-80. doi: 10.1016/j.bmc.2013.09.021.

PMID:
24095016
12.

Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.

Li X, Liu JL, Yang XH, Lu X, Zhao TT, Gong HB, Zhu HL.

Bioorg Med Chem. 2012 Jul 15;20(14):4430-6. doi: 10.1016/j.bmc.2012.05.031.

PMID:
22705022
13.

Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.

Cai J, Wei H, Hong KH, Wu X, Cao M, Zong X, Li L, Sun C, Chen J, Ji M.

Eur J Med Chem. 2015;96:1-13. doi: 10.1016/j.ejmech.2015.04.002.

PMID:
25874326
14.

Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.

Seidel C, Schnekenburger M, Zwergel C, Gaascht F, Mai A, Dicato M, Kirsch G, Valente S, Diederich M.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3797-801. doi: 10.1016/j.bmcl.2014.06.067.

PMID:
25042254
15.

Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.

Zhang Y, Feng J, Liu C, Zhang L, Jiao J, Fang H, Su L, Zhang X, Zhang J, Li M, Wang B, Xu W.

Bioorg Med Chem. 2010 Mar 1;18(5):1761-72. doi: 10.1016/j.bmc.2010.01.060.

PMID:
20171895
16.

The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.

Zhang X, Zhang J, Tong L, Luo Y, Su M, Zang Y, Li J, Lu W, Chen Y.

Bioorg Med Chem. 2013 Jun 1;21(11):3240-4. doi: 10.1016/j.bmc.2013.03.049.

PMID:
23602523
17.

Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.

Cai J, Wei H, Hong KH, Wu X, Zong X, Cao M, Wang P, Li L, Sun C, Chen B, Zhou G, Chen J, Ji M.

Bioorg Med Chem. 2015 Jul 1;23(13):3457-71. doi: 10.1016/j.bmc.2015.04.028.

PMID:
25953722
18.

Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents.

Huang D, Li X, Sun L, Xiu Z, Nishino N.

J Pept Sci. 2012 Apr;18(4):242-51. doi: 10.1002/psc.2392.

PMID:
22253009
19.

Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.

Chen GL, Wang LH, Wang J, Chen K, Zhao M, Sun ZZ, Wang S, Zheng HL, Yang JY, Wu CF.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3891-5. doi: 10.1016/j.bmcl.2013.04.067.

PMID:
23707260
20.

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):294-8. doi: 10.1016/j.bmcl.2009.10.118.

PMID:
19906529

Supplemental Content

Support Center